Interesting things are taking place behind the scenes as cannabis prohibition moves to a grinding halt.
Key organizations like U.S. Pharmacopeial Convention (USP), a scientific nonprofit organization that sets standards for the identity, strength, quality, and purity of medicines, food ingredients, and dietary supplements manufactured, distributed and consumed worldwide, has begun evaluating the advisability and feasibility of developing USP standards for medical marijuana.
According to Wikipedia, USP establishes written (documentary) and physical (reference) standards for medicines, food ingredients, dietary supplement products, and ingredients. These standards are used by regulatory agencies and manufacturers to help to ensure that these products are of the appropriate identity, as well as strength, quality, purity, and consistency.
Prescription and over-the-counter medicines available in the United States must, by federal law, meet USP-NF public standards, where such standards exist. Many other countries use the USP-NF instead of issuing their own pharmacopeia, or to supplement their government pharmacopeia.
CBE recently discovered that USP, the Food and Drug Administration and key industry stakeholders had recently met to do just that, CBE contacted USP and was pointed in the direction of a link to an abstract on their site, www.usp.org, by Christine Feaster, Vice President, Head of Strategic Marketing and Program Operations — Dietary Supplements & Herbal Medicines at USP to the following document which provides a scientific abstract discussing the current regulatory and scientific landscape regarding medical cannabis.
You will have to sign-up for an account to access the document (it is a little tricky to navigate their site to find the document which encourages all stakeholders, CBE’s stakeholder readers, licensees, ancillary businesses and regulatory readers, to review the document we are citing and communicate your input and feedback directly to USP.
Correspondence should be addressed to: Gabriel I. Giancaspro, Vice President, Science-DS & Herbal Medicines, US Pharmacopeial Convention, 12601 Twinbrook Parkway, Rockville, MD 20852-1790; tel. +1.301.816.8343; e-mail: [email protected]
In short, the document lays the historical background of cannabis in the U.S. and abroad. It also cites:
The document also outlines a variety of approaches for developing Compendial Standards for Cannabis. USP believes that its experience in developing quality standards criteria for herbal medicines, either as dietary supplements or pharmaceuticals could be used as a foundation of standard development for cannabis products.
The Cannabis Industry, USP and federal regulatory groups like the FDA, U.S. Department of Agriculture, National Institutes of Health, etc., have the experience in making cannabis safety part of the best oversight structure in the world and it is incumbent on all of us to seek this mutually beneficial partnership to advance the legalization of medical and adult use cannabis in order to set up a totally transparent, federally regulated industry and to end prohibition sooner than later.
Please review the cited document and let’s all reach out to USP today to move to ball forward.
Rob Meagher, CBE’s Founder, President and Editor-in-Chief is a 30 year veteran of the media world. His career has spanned from stints representing the Washington Post, USA Weekend, Reader’s Digest, Financial World & Corporate Finance to the technology world where he worked at International Data Group and Ziff Davis where he was part of the launch team for The Web Magazine, Yahoo Internet Life, Smart Business and Expedia Travels before starting his own marketing and Publisher’s Representative Firm. He also ran all print and online media sales and marketing for the Society for Human Resource Management before partnering with Forbes and then Fortune to create Special Sections covering a variety of topics. Rob, who started CBE Press in 2014, can be contacted at [email protected]
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Notify me of follow-up comments by email.
Notify me of new posts by email.
By Griffin Thorne, Attorney at Harris Bricken Since the passage of the 2018 Farm Bill, the hemp CBD industry has been eagerly awaiting FDA CBD regulations. In that time, FDA…
The US Food and Drug Administration has finalized a 2020 draft guidance outlining how sponsors and investigators can conduct clinical trials for certain drugs containing cannabis or cannabis-derived compounds without…
The New Hampshire Legislature is once again debating recreational use of marijuana but efforts to legalize it still face significant hurdles. In the decade since the state legalized medical marijuana,…
Behind closed doors, Mississippi’s eight-person medical cannabis office is struggling against its workload. The Health Department office charged by the Legislature with running Mississippi’s new medical marijuana program is steeped…